During the past decade, Oklahoma Foundation for Cardiovascular Research conducted 43 clinical trials. In the 10-year time frame, 43 clinical trials started and 35 clinical trials were completed, i.e. on average, 81.4% percent of trials that started reached the finish line to date. In the past 5 years, 17 clinical trials started and 16 clinical trials were completed. i.e. 94.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Oklahoma Foundation for Cardiovascular Research" #1 sponsor was "Boston Scientific Corporation" with 11 trials, followed by "Medtronic Cardiac Rhythm and Heart Failure" with 9 trials sponsored, "Pfizer" with 7 trials sponsored, "Edwards Lifesciences" with 6 trials sponsored and "Boehringer Ingelheim" with 6 trials sponsored. Other sponsors include 54 different institutions and companies that sponsored additional 47 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Oklahoma Foundation for Cardiovascular Research" #1 collaborator was "Eli Lilly and Company" with 4 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 3 trials as a collaborator, "Abbott Medical Devices" with 1 trials as a collaborator, "Boston Scientific Corporation" with 1 trials as a collaborator and "Brigham and Women's Hospital" with 1 trials as a collaborator. Other collaborators include 12 different institutions and companies that were collaborators in the rest 22 trials.

According to Clinical.Site data, the most researched conditions in "Oklahoma Foundation for Cardiovascular Research" are "Coronary Artery Disease" (14 trials), "Heart Failure" (13 trials), "Atrial Fibrillation" (8 trials), "Acute Coronary Syndrome" (3 trials) and "Aortic Stenosis" (3 trials). Many other conditions were trialed in "Oklahoma Foundation for Cardiovascular Research" in a lesser frequency.

Most popular intervention types in "Oklahoma Foundation for Cardiovascular Research" are "Drug" (51 trials), "Device" (40 trials), "Other" (12 trials), "Procedure" (5 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (28 trials), "Apixaban" (4 trials), "Empagliflozin" (4 trials), "K-877" (3 trials) and "TAXUS Liberté-SR" (3 trials). Other intervention names were less common.

The vast majority of trials in "Oklahoma Foundation for Cardiovascular Research" are 97 trials for "All" genders.

Currently, there are NaN active trials in "Oklahoma Foundation for Cardiovascular Research". undefined are not yet recruiting, 7 are recruiting, 14 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 63 completed trials in Oklahoma Foundation for Cardiovascular Research, undefined suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in Oklahoma Foundation for Cardiovascular Research, 1 "Phase 1" clinical trials were conducted, 21 "Phase 2" clinical trials and 41 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 25 trials that are defined as “Not Applicable".